Mechanisms and therapeutic implications of hypermutation in gliomas.

Animals Antineoplastic Agents, Alkylating / pharmacology Brain Neoplasms / genetics DNA Mismatch Repair / genetics Gene Frequency Genome, Human / drug effects Glioma / genetics Humans Male Mice Microsatellite Repeats / drug effects Mutagenesis / drug effects Mutation / drug effects Phenotype Prognosis Programmed Cell Death 1 Receptor / antagonists & inhibitors Sequence Analysis, DNA Temozolomide / pharmacology Xenograft Model Antitumor Assays

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2020
Historique:
received: 22 07 2019
accepted: 04 03 2020
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 6 6 2020
Statut: ppublish

Résumé

A high tumour mutational burden (hypermutation) is observed in some gliomas

Identifiants

DOI: 10.1038/s41586-020-2209-9 PMID: 32322066 PMC: PMC8235024
pubmed: 32322066
doi: 10.1038/s41586-020-2209-9
pii: 10.1038/s41586-020-2209-9
pmc: PMC8235024
mid: NIHMS1572083
doi:

Substances chimiques

Antineoplastic Agents, Alkylating 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Temozolomide YF1K15M17Y

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-523

Subventions

Organisme : NCI NIH HHS
ID : R01 CA188228
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA201592
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS091620
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA095616
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA142536
Pays : United States
Organisme : NHGRI NIH HHS
ID : T32 HG002295
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215489
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA201592
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA165962
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS110942
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233331
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA163205
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219943
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987–3991 (2006).
pubmed: 16618716 doi: 10.1158/0008-5472.CAN-06-0127 pmcid: 7212022
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).
pubmed: 24336570 doi: 10.1126/science.1239947
Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).
pubmed: 27270107 pmcid: 5627776 doi: 10.1038/ng.3590
Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019).
pubmed: 31748746 doi: 10.1038/s41586-019-1775-1 pmcid: 6897368
Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).
pubmed: 27001570 doi: 10.1200/JCO.2016.66.6552
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070 pmcid: 4993154 doi: 10.1126/science.aaa1348
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
pubmed: 26028255 pmcid: 4481136 doi: 10.1056/NEJMoa1500596
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
pubmed: 26940869 pmcid: 4984254 doi: 10.1126/science.aaf1490
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
pubmed: 24120142 pmcid: 3910500 doi: 10.1016/j.cell.2013.09.034
Brat, D. J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
pubmed: 26061751 doi: 10.1056/NEJMoa1402121
Louis, D. N. et al. World Health Organization Histological Classification of Tumours of the Central Nervous System (ed. 2) (International Agency for Research on Cancer, 2016).
Cahill, D. P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038–2045 (2007).
pubmed: 17404084 pmcid: 2873832 doi: 10.1158/1078-0432.CCR-06-2149
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 3776390 doi: 10.1038/nature12477
Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023–1031 (2013).
pubmed: 24142049 pmcid: 5710001 doi: 10.1038/nbt.2696
Sholl, L. M. et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062 (2016).
pubmed: 27882345 pmcid: 5111542 doi: 10.1172/jci.insight.87062
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
pubmed: 28481359 pmcid: 5461196 doi: 10.1038/nm.4333
Campbell, B. B. et al. Comprehensive analysis of hypermutation in human cancer. Cell 171, 1042–1056.e10 (2017).
pubmed: 29056344 pmcid: 5849393 doi: 10.1016/j.cell.2017.09.048
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
pubmed: 15758009 doi: 10.1056/NEJMoa043330
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344–350 (2013).
pubmed: 23071237 doi: 10.1200/JCO.2012.43.2229
Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
pubmed: 27111033 pmcid: 4936490 doi: 10.1038/ng.3557
Berends, M. J. et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am. J. Hum. Genet. 70, 26–37 (2002).
pubmed: 11709755 doi: 10.1086/337944
Yang, G. et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 6, 139–150 (2004).
pubmed: 15324697 doi: 10.1016/j.ccr.2004.06.024
Ollier, E. et al. Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. Fundam. Clin. Pharmacol. 31, 347–358 (2017).
pubmed: 27933657 doi: 10.1111/fcp.12259
Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1–10 (2020).
pubmed: 31682550 doi: 10.1200/JCO.19.02105
Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
pubmed: 29186113 doi: 10.1038/nature24673
Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485–491 (2019).
pubmed: 31048490 pmcid: 6685207 doi: 10.1126/science.aau0447
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pubmed: 30894752 pmcid: 6954100 doi: 10.1038/s41586-019-1032-7
Gejman, R. S. et al. Rejection of immunogenic tumor clones is limited by clonal fraction. eLife 7, e41090 (2018).
pubmed: 30499773 pmcid: 6269121 doi: 10.7554/eLife.41090
Gylling, A. H. et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 29, 1351–1359 (2008).
pubmed: 18550572 doi: 10.1093/carcin/bgn133
Herrlinger, U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393, 678–688 (2019).
pubmed: 30782343 doi: 10.1016/S0140-6736(18)31791-4
Jonsson, P. et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin. Cancer Res. 25, 5537–5547 (2019).
pubmed: 31263031 pmcid: 6753053 doi: 10.1158/1078-0432.CCR-19-0032
Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).
pubmed: 28420421 pmcid: 5395719 doi: 10.1186/s13073-017-0424-2
Consortium, A. P. G.; AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).
doi: 10.1158/2159-8290.CD-17-0151
Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).
pmcid: 3919969 doi: 10.1038/ng.2764
Garcia, E. P. et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab. Med. 141, 751–758 (2017).
pubmed: 28557599 doi: 10.5858/arpa.2016-0527-OA
Ramkissoon, S. H. et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-oncol. 19, 986–996 (2017).
pubmed: 28104717 pmcid: 5570190
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 pmcid: 3833702 doi: 10.1038/nbt.2514
Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423–E2429 (2015).
pubmed: 25703262 doi: 10.1002/humu.22771 pmcid: 7350419
Bi, W. L. et al. Clinical identification of oncogenic drivers and copy-number alterations in pituitary tumors. Endocrinology 158, 2284–2291 (2016).
doi: 10.1210/en.2016-1967
Abo, R. P. et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 43, e19 (2015).
pubmed: 25428359 doi: 10.1093/nar/gku1211
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
Karczewski, K. J. et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. Preprint at https://www.biorxiv.org/content/10.1101/531210v2 (2019).
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
pubmed: 29165669 doi: 10.1093/nar/gkx1153
Sun, J. X. et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLOS Comput. Biol. 14, e1005965 (2018).
pubmed: 29415044 pmcid: 5832436 doi: 10.1371/journal.pcbi.1005965
Garofalo, A. et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 8, 79 (2016).
pubmed: 27460824 pmcid: 4962446 doi: 10.1186/s13073-016-0333-9
Trabucco, S. E. et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J. Mol. Diagn. 21, 1053–1066 (2019).
pubmed: 31445211 doi: 10.1016/j.jmoldx.2019.06.011 pmcid: 7807551
Papke, D. J. Jr et al. Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. Mod. Pathol. 31, 1882–1890 (2018).
pubmed: 29955144 doi: 10.1038/s41379-018-0091-x
Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat. Genet. 48, 126–133 (2016).
pubmed: 26656846 doi: 10.1038/ng.3469
Gehring, J. S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31, 3673–3675 (2015).
pubmed: 26163694 pmcid: 4817139
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pubmed: 26899170 pmcid: 4762164 doi: 10.1186/s13059-016-0893-4
Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271–281.e277 (2018).
pubmed: 29596782 pmcid: 6075717 doi: 10.1016/j.cels.2018.03.002
Francis, J. M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956–971 (2014).
pubmed: 24893890 pmcid: 4125473 doi: 10.1158/2159-8290.CD-13-0879
Lodato, M. A. et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 359, 555–559 (2018).
pubmed: 29217584 doi: 10.1126/science.aao4426
Bohrson, C. L. et al. Linked-read analysis identifies mutations in single-cell DNA-sequencing data. Nat. Genet. 51, 749–754 (2019).
pubmed: 30886424 pmcid: 6900933 doi: 10.1038/s41588-019-0366-2
Cortes-Ciriano, I., Lee, S., Park, W. Y., Kim, T. M. & Park, P. J. A molecular portrait of microsatellite instability across multiple cancers. Nat. Commun. 8, 15180 (2017).
pubmed: 28585546 pmcid: 5467167 doi: 10.1038/ncomms15180
Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601–2602 (2011).
pubmed: 21803805 pmcid: 3167057 doi: 10.1093/bioinformatics/btr446
Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817 (2012).
doi: 10.1093/bioinformatics/bts271 pubmed: 22581179
Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).
pubmed: 23303777 pmcid: 3616734 doi: 10.1093/nar/gks1443
Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531–534 (2018).
pubmed: 29941871 pmcid: 6528031 doi: 10.1038/s41592-018-0036-9
Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013).
pubmed: 23415222 pmcid: 3575604 doi: 10.1016/j.cell.2013.01.019
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
pubmed: 24390350 pmcid: 4048962 doi: 10.1038/nature12912
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
pubmed: 22544022 pmcid: 4383288 doi: 10.1038/nbt.2203
McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4

Auteurs

Mehdi Touat (M)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. mehdi.touat@gmail.com.
Broad Institute of Harvard and MIT, Cambridge, MA, USA. mehdi.touat@gmail.com.
Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France. mehdi.touat@gmail.com.

Yvonne Y Li (YY)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Adam N Boynton (AN)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.

Liam F Spurr (LF)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

J Bryan Iorgulescu (JB)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham & Women's Hospital, Boston, Harvard Medical School, MA, USA.
ORCID: 0000-0003-1405-3667

Craig L Bohrson (CL)

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Bioinformatics and Integrative Genomics PhD Program, Harvard Medical School, Boston, MA, USA.

Isidro Cortes-Ciriano (I)

European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.

Cristina Birzu (C)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Jack E Geduldig (JE)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Kristine Pelton (K)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Mary Jane Lim-Fat (MJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-4317-5770

Sangita Pal (S)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Ruben Ferrer-Luna (R)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Foundation Medicine Inc., Cambridge, MA, USA.

Shakti H Ramkissoon (SH)

Foundation Medicine Inc., Cambridge, MA, USA.
Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Frank Dubois (F)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Charlotte Bellamy (C)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Naomi Currimjee (N)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Juliana Bonardi (J)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Kenin Qian (K)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
ORCID: 0000-0003-0296-6207

Patricia Ho (P)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
ORCID: 0000-0002-4622-8188

Seth Malinowski (S)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Leon Taquet (L)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Robert E Jones (RE)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Aniket Shetty (A)

Center for Patient Derived Models, Dana-Farber Cancer Institute, Boston, MA, USA.

Kin-Hoe Chow (KH)

Center for Patient Derived Models, Dana-Farber Cancer Institute, Boston, MA, USA.

Radwa Sharaf (R)

Foundation Medicine Inc., Cambridge, MA, USA.

Dean Pavlick (D)

Foundation Medicine Inc., Cambridge, MA, USA.

Lee A Albacker (LA)

Foundation Medicine Inc., Cambridge, MA, USA.

Nadia Younan (N)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Capucine Baldini (C)

Drug Development Department (DITEP), INSERM U1015, Université Paris Saclay, Gustave Roussy, Villejuif, France.

Maïté Verreault (M)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Marine Giry (M)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Erell Guillerm (E)

Unité fonctionnelle d'Oncogénétique et Angiogénétique Moléculaire, Département de génétique, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.

Samy Ammari (S)

Department of Diagnostic Radiology, Gustave Roussy, Villejuif, France.
IR4M (UMR8081), Université Paris-Sud, Centre National de la Recherche Scientifique, Orsay, France.

Frédéric Beuvon (F)

AP-HP, Université Paris Descartes, Hôpital Cochin, Service d'Anatomie et Cytologie Pathologiques, Paris, France.

Karima Mokhtari (K)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie Laboratoire Escourolle, Paris, France.

Agusti Alentorn (A)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Caroline Dehais (C)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Caroline Houillier (C)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Florence Laigle-Donadey (F)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Dimitri Psimaras (D)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Eudocia Q Lee (EQ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Lakshmi Nayak (L)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

J Ricardo McFaline-Figueroa (JR)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Alexandre Carpentier (A)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Philippe Cornu (P)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Laurent Capelle (L)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Bertrand Mathon (B)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Jill S Barnholtz-Sloan (JS)

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
ORCID: 0000-0001-6190-9304

Arnab Chakravarti (A)

Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH, USA.

Wenya Linda Bi (WL)

Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

E Antonio Chiocca (EA)

Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

Katie Pricola Fehnel (KP)

Department of Neurosurgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Sanda Alexandrescu (S)

Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Susan N Chi (SN)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

Daphne Haas-Kogan (D)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Tracy T Batchelor (TT)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Garrett M Frampton (GM)

Foundation Medicine Inc., Cambridge, MA, USA.

Brian M Alexander (BM)

Foundation Medicine Inc., Cambridge, MA, USA.
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Raymond Y Huang (RY)

Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Azra H Ligon (AH)

Department of Pathology, Brigham & Women's Hospital, Boston, Harvard Medical School, MA, USA.

Florence Coulet (F)

Unité fonctionnelle d'Oncogénétique et Angiogénétique Moléculaire, Département de génétique, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.

Jean-Yves Delattre (JY)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
Onconeurotek Tumor Bank, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Khê Hoang-Xuan (K)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

David M Meredith (DM)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham & Women's Hospital, Boston, Harvard Medical School, MA, USA.

Sandro Santagata (S)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham & Women's Hospital, Boston, Harvard Medical School, MA, USA.
Ludwig Center at Harvard Medical School, Harvard Medical School, Boston, MA, USA.
Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-7528-9668

Alex Duval (A)

Sorbonne Université, Inserm, UMR 938, Centre de Recherche Saint Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France.
ORCID: 0000-0003-1534-1724

Marc Sanson (M)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
Onconeurotek Tumor Bank, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Andrew D Cherniack (AD)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0003-0470-0111

Patrick Y Wen (PY)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

David A Reardon (DA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Aurélien Marabelle (A)

Drug Development Department (DITEP), INSERM U1015, Université Paris Saclay, Gustave Roussy, Villejuif, France.

Peter J Park (PJ)

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-9378-960X

Ahmed Idbaih (A)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Rameen Beroukhim (R)

Broad Institute of Harvard and MIT, Cambridge, MA, USA. rameen_beroukhim@dfci.harvard.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. rameen_beroukhim@dfci.harvard.edu.
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. rameen_beroukhim@dfci.harvard.edu.
ORCID: 0000-0001-6303-3609

Pratiti Bandopadhayay (P)

Broad Institute of Harvard and MIT, Cambridge, MA, USA. pratiti_bandopadhayay@dfci.harvard.edu.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. pratiti_bandopadhayay@dfci.harvard.edu.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA. pratiti_bandopadhayay@dfci.harvard.edu.

Franck Bielle (F)

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie Laboratoire Escourolle, Paris, France. franck.bielle@aphp.fr.

Keith L Ligon (KL)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. keith_ligon@dfci.harvard.edu.
Broad Institute of Harvard and MIT, Cambridge, MA, USA. keith_ligon@dfci.harvard.edu.
Department of Pathology, Brigham & Women's Hospital, Boston, Harvard Medical School, MA, USA. keith_ligon@dfci.harvard.edu.
Center for Patient Derived Models, Dana-Farber Cancer Institute, Boston, MA, USA. keith_ligon@dfci.harvard.edu.
Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. keith_ligon@dfci.harvard.edu.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Actions chimiques et utilisations › Actions toxiques › Noxas › Agents alcoylants › Antinéoplasiques alcoylants › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Réparation de l'ADN › Réparation de mésappariement de l'ADN › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Fréquence d'allèle › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Structures génétiques › Génome › Génome humain › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées en tandem › Répétitions microsatellites › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Mutagenèse › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Variation génétique › Mutation › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Phénomènes génétiques › Phénotype › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Diagnostic › Pronostic › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Dacarbazine › Témozolomide › Mechanisms and therapeutic implications of...
Recherchemedicale.com › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Mechanisms and therapeutic implications of...